Welcome to Chinese Journal of Clinical Pharmacology and Therapeutics,Today is Share:

Chinese Journal of Clinical Pharmacology and Therapeutics ›› 1998, Vol. 3 ›› Issue (4): 246-249.

Previous Articles     Next Articles

Application of simvastatin in hyperlipidemic patients after renal transplantation1

XU Feng, FAN Li-Pei2, WU Zhao-Hui, ZOU Heng-Qing, ZHANG Zhong-Yi   

  1. Department of Clinical Pharmacology,2Department of Kidney Transplantation,Zhujiang Hosptal,First Military Medical University,Guangzhou 510282
  • Received:1998-08-24 Revised:1998-09-21 Online:1998-12-26 Published:2020-12-01

Abstract: Aim To study the effect and safety of simvastatin in hyperlipidemic patients after renalt ransplantation.Methods Seventeen hyperlipidemic patients after renalt ransplantation(with to talcholesterol level higher than 6.2 mmol/L)were given simvastatin 10 mg/day for 1 month.The venous blood was collected from an antecubital vein.Plasma lipid and cyclosporine concentration in w hole blood w ere determined before and 1 month after simvastatin administration.Cholesterol (TC)and triglyceride (TG)in plasma w ere determined by standard enzymatical procedures on a Biochem autoanalyzer (Beckman,USA).The blood cyclosporine concentration was determined by specific FPIA method.Results Plasma TC levels w ere decreased markedly from 8.74 ±2.18 mmol/L to 7.59 ±3.28 mmol/L (P<0.05),TG levels were kept unchanged,and the whole blood cyclosporine concentrations w ere increased significantly from 185.31 ±39.02 ng/ml to 257.33 ±57.78 ng /ml (P<0.01)after 1 month of simvastatin administration in 17 recipients.No severe adverse drug reactions were observed.Conclusion Low dose simvastatin can be safely used to treat hyperlipidemic patients after renal transplantation.

Key words: simvastatin, cyclosporine, hyperlipidemia, kidney transplantation

CLC Number: